ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,303.27
      0.12%
      US Tech 100
      18,062.00
      -0.10%
      Dow Jones
      40,003.59
      0.34%
      Brent Oil
      83.76
      0.00%
      Bitcoin
      67,093.31
      0.02%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Lexicon Pharmaceuticals Inc (LXRX)

      7. Lexicon Pharmaceuticals Inc (LXRX) News

      LXRX

      Lexicon Pharmaceuticals (LXRX)

      Lexicon Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:LXRX
      DateTimeSourceHeadlineSymbolCompany
      3:00PMiHub NewswireFeaturedMusic Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements
      05/16/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/14/20245:05PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/14/20247:00AMGlobeNewswire Inc.New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection FractionNASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/13/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/13/20244:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/13/20244:03PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/13/20244:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/13/20244:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/10/20245:14PMEdgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/10/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/09/20247:30AMGlobeNewswire Inc.Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024NASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/02/20244:05PMGlobeNewswire Inc.Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:LXRXLexicon Pharmaceuticals Inc
      04/29/20249:00AMGlobeNewswire Inc.Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon PharmaceuticalsNASDAQ:LXRXLexicon Pharmaceuticals Inc
      04/29/20247:00AMGlobeNewswire Inc.Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024NASDAQ:LXRXLexicon Pharmaceuticals Inc
      04/18/20248:00AMGlobeNewswire Inc.Lexicon Pharmaceuticals to Host 2024 Investor DayNASDAQ:LXRXLexicon Pharmaceuticals Inc
      04/03/20248:00AMGlobeNewswire Inc.Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
      03/25/20249:20AMGlobeNewswire Inc.Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & ExpoNASDAQ:LXRXLexicon Pharmaceuticals Inc
      03/12/20248:00AMGlobeNewswire Inc.New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney DiseaseNASDAQ:LXRXLexicon Pharmaceuticals Inc
      03/11/20244:25PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:LXRXLexicon Pharmaceuticals Inc
      03/11/20247:26AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXRXLexicon Pharmaceuticals Inc
      03/11/20247:15AMGlobeNewswire Inc.Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:LXRXLexicon Pharmaceuticals Inc
      03/11/20247:05AMGlobeNewswire Inc.Lexicon Announces Oversubscribed $250 Million Private Placement of Equity SecuritiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      03/11/20247:00AMGlobeNewswire Inc.Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDANASDAQ:LXRXLexicon Pharmaceuticals Inc
      02/29/20244:29PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      02/29/20244:28PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      02/12/20244:19PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      02/12/20244:18PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      02/12/20244:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      02/12/20244:16PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:LXRX